Chronic lymphocytic leukemia

Alexey V. Danilov; Veronika Bachanova

doi:10.1007/978-3-030-53626-8_22

Chronic lymphocytic leukemia

Alexey V. Danilov
, Veronika Bachanova

Medicine - Hematology, Oncology, Transplant

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Introduction of novel targeted therapies resulted in a significant paradigm shift in the treatment of CLL in recent years, leading to improved patient outcomes and arguably limited the role of cellular therapies. However, remaining unmet needs, in particular patients with high-risk disease (those with TP53 aberrations or complex karyotype) and those progressing on novel agents, justify continued interest in cellular therapies in this disease, including allogeneic cell transplantation (HCT) and chimeric antigen receptor T (CAR-T) cells. Here, we summarize the current state of affairs in this field.

Original language	English (US)
Title of host publication	Blood and Marrow Transplant Handbook
Subtitle of host publication	Comprehensive Guide for Patient Care
Publisher	Springer International Publishing
Pages	347-353
Number of pages	7
ISBN (Electronic)	9783030536268
ISBN (Print)	9783030536251
DOIs	https://doi.org/10.1007/978-3-030-53626-8_22
State	Published - Jan 13 2021

Bibliographical note

Publisher Copyright:
© Springer Nature Switzerland AG 2021.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1007/978-3-030-53626-8_22

Find It

Find It at U of M Libraries

Cite this

@inbook{7af1fe0738da44bb87cb8a22ae655b15,

title = "Chronic lymphocytic leukemia",

abstract = "Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Introduction of novel targeted therapies resulted in a significant paradigm shift in the treatment of CLL in recent years, leading to improved patient outcomes and arguably limited the role of cellular therapies. However, remaining unmet needs, in particular patients with high-risk disease (those with TP53 aberrations or complex karyotype) and those progressing on novel agents, justify continued interest in cellular therapies in this disease, including allogeneic cell transplantation (HCT) and chimeric antigen receptor T (CAR-T) cells. Here, we summarize the current state of affairs in this field.",

author = "Danilov, \{Alexey V.\} and Veronika Bachanova",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2021",

month = jan,

day = "13",

doi = "10.1007/978-3-030-53626-8\_22",

language = "English (US)",

isbn = "9783030536251",

pages = "347--353",

booktitle = "Blood and Marrow Transplant Handbook",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Chronic lymphocytic leukemia

AU - Danilov, Alexey V.

AU - Bachanova, Veronika

PY - 2021/1/13

Y1 - 2021/1/13

N2 - Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Introduction of novel targeted therapies resulted in a significant paradigm shift in the treatment of CLL in recent years, leading to improved patient outcomes and arguably limited the role of cellular therapies. However, remaining unmet needs, in particular patients with high-risk disease (those with TP53 aberrations or complex karyotype) and those progressing on novel agents, justify continued interest in cellular therapies in this disease, including allogeneic cell transplantation (HCT) and chimeric antigen receptor T (CAR-T) cells. Here, we summarize the current state of affairs in this field.

AB - Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Introduction of novel targeted therapies resulted in a significant paradigm shift in the treatment of CLL in recent years, leading to improved patient outcomes and arguably limited the role of cellular therapies. However, remaining unmet needs, in particular patients with high-risk disease (those with TP53 aberrations or complex karyotype) and those progressing on novel agents, justify continued interest in cellular therapies in this disease, including allogeneic cell transplantation (HCT) and chimeric antigen receptor T (CAR-T) cells. Here, we summarize the current state of affairs in this field.

UR - https://www.scopus.com/pages/publications/105010287781

UR - https://www.scopus.com/pages/publications/105010287781#tab=citedBy

U2 - 10.1007/978-3-030-53626-8_22

DO - 10.1007/978-3-030-53626-8_22

M3 - Chapter

AN - SCOPUS:105010287781

SN - 9783030536251

SP - 347

EP - 353

BT - Blood and Marrow Transplant Handbook

PB - Springer International Publishing

ER -

Chronic lymphocytic leukemia

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this